ArticleBlood advances2017
Impact of genomic alterations on outcomes in myelofibrosis patients undergoing JAK1/2 inhibitor therapy.
Article in Blood advances, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03959371 (Observational, Retrospective and Prospective Study on the Use of Ruxolitinib in Myelofibrosis Patients in Lombardy, Italy), which is not on this map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Observational, Retrospective and Prospective Study on the Use of Ruxolitinib in Myelofibrosis Patients in Lombardy, Italy
Who cites it
42 citing papers in PubMed, 65 citations in OpenAlex.
- Addition of navitoclax to ruxolitinib for patients with myelofibrosis with progression or suboptimal response.Blood neoplasia · 2025Trial
- Addition of Navitoclax to Ongoing Ruxolitinib Therapy for Patients With Myelofibrosis With Progression or Suboptimal Response: Phase II Safety and Efficacy.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022Trial
- Association of frailty with clinical outcomes in myelofibrosis: a retrospective cohort study.British journal of haematology · 2021Trial
- Ruxolitinib Therapy Followed by Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation for Myelofibrosis: Myeloproliferative Disorders Research Consortium 114 Study.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2019Trial
- A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis.Blood · 2018Trial
- Real-world validation study of the LSC17 score for risk prediction in patients with newly diagnosed acute myeloid leukemia.Haematologica · 2026Article
- Pathogenesis and management of high molecular risk myeloproliferative neoplasms.Haematologica · 2025Review
- Relationship between additional mutations at diagnosis and treatment response in patients with essential thrombocythemia.Blood advances · 2025Article
- Advances in Stem Cell Transplantation for Myelofibrosis.Current hematologic malignancy reports · 2024Review
- BIRC5 upregulation enhances DNMT3A-mutant T-ALL cell survival and pathogenesis.Blood neoplasia · 2024Article
- Prognostic and Predictive Models in Myelofibrosis.Current hematologic malignancy reports · 2024Review
- Outcomes of intensive and nonintensive blast-reduction strategies in accelerated and blast-phase MPN.Blood advances · 2024Article
- Molecular Genetic Profile of Myelofibrosis: Implications in the Diagnosis, Prognosis, and Treatment Advancements.Cancers · 2024Review
- Myelofibrosis and allogeneic transplantation: critical points and challenges.Frontiers in oncology · 2024Review
- Article
- Association of Myelofibrosis Phenotypes with Clinical Manifestations, Molecular Profiles, and Treatments.Cancers · 2023Review
- Review
- Biological drivers of clinical phenotype in myelofibrosis.Leukemia · 2023Review
- Impact of mutations on pregnancy outcome in patients with myeloproliferative neoplasms.EJHaem · 2023Article
- Biallelic disruption of DDX41 activity is associated with distinct genomic and immunophenotypic hallmarks in acute leukemia.Frontiers in oncology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In myelofibrosis (MF), driver mutations in
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.